How to evaluate digital treatments for insomnia and anxiety

Now more than ever, it’s crucial for companies to invest in effective workforce solutions for managing insomnia and anxiety. In this guide, we explore the key factors to consider so you can select a solution that meets the needs of your employees and supports a healthy workplace culture.

Insomnia and anxiety aren’t just personal concerns — they’re major workplace issues, too. Insomnia-related absenteeism and presenteeism cost US employers $2,280 per employee with insomnia annually — and employees with anxiety disorders also have high productivity costs — to the tune of $1,366 per employee per year.

Now more than ever, it’s crucial for companies to invest in effective workforce solutions for managing insomnia and anxiety. In this guide, we explore the key factors to consider so you can select a solution that meets the needs of your employees and supports a healthy workplace culture.

Key insights:

  • Understanding how insomnia and anxiety are linked with employee performance and health care costs
  • Learning about the range of workforce solutions for insomnia and anxiety
  • Identifying what digital treatments can do for your workforce
  • Assessing how digital treatments stack up against other options in the market

A peek inside:

Copy Link

Download the guide

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively.

1. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.2. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., … & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.3. Wilson, S., Anderson, K., Baldwin, D., Dijk, D. J., Espie, A., Espie, C., … & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. Journal of Psychopharmacology, 33(8), 923-947.4. King’s Technology Evaluation Centre. (2017, November 9). Overview: Health app: SLEEPIO for adults with poor Sleep: Advice. NICE. https://www.nice.org.uk/advice/mib129.5. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and Anxiety, 37(12), 1168-1178.

DOC-3046 Effective 11/2023